Cargando…
The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
Vaccination is one of the best ways to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. Among the various SARS-CoV-2 vaccines approved for use, the BBIBP-CorV inactivated vaccine has been widely used in 93 countries. In order to understand deeply the protective mech...
Autores principales: | Wang, Qinjin, Ning, Jie, Chen, Ying, Li, Bin, Shi, Liang, He, Taojun, Zhang, Fang, Chen, Xingchi, Zhai, Aixia, Wu, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672472/ https://www.ncbi.nlm.nih.gov/pubmed/36406456 http://dx.doi.org/10.3389/fmicb.2022.1008420 |
Ejemplares similares
-
BBIBP-CorV: Hepatitis: case report
Publicado: (2022) -
BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022) -
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022) -
BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022) -
BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)